Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 3/20 | 0.34 |
| ▸ | FNTA | P49354 | 2/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL2268534 | 0.90 | FDPS (0.60) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL15555988 | 0.89 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL18714 | 0.89 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| SCHEMBL669220 | 0.88 | FDPS (0.50) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL25284822 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL9632051 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL3305647 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL21246913 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL22717549 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL36119 | 0.86 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| EP-3947408-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | Nucana PLC (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| WO-2020201751-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2007110624-A2 | IMMOBILISED REAGENT | UNIVERSITY COURT OF THE UNIVERSITY OFEDINBURGH (GB) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NUDT1, ITPA, MTAP | FDPS 697/4885BLM 1553/4885TDP1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.